ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

UPI (MM)

1.20
0.00 (0.00%)
08 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:UPI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.20 0 00:00:00

Uroplasty to Present at the 11th Annual JMP Securities Research Conference

07/05/2012 9:05pm

PR Newswire (US)


(MM) (NASDAQ:UPI)
Historical Stock Chart


From Nov 2019 to Nov 2024

Click Here for more (MM) Charts.

MINNEAPOLIS, May 7, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the 11th Annual JMP Securities Research Conference at 12:30 pm PT on Monday, May 14, 2012 at the Ritz-Carlton Hotel in San Francisco.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://wsw.com/webcast/jmp17/upi/, or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:



Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Medi Jiwani, Vice President, CFO, Treasurer

Chris Gale (Media), 646.201.5431

952.426.6140



SOURCE Uroplasty, Inc.

Copyright 2012 PR Newswire

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart